News and Press Releases
KITE Shares New Data at EHA 2024 Which Demonstrates Positive Patient Outcomes and Advances in Delivery of CAR T-Cell Therapy
Analysis comparing real-world and clinical trial data shows Yescarta (Axicabtagene Ciloleucel) has higher manufacturing success rates and improved T-cell performance, respectively, in second-line vs third-line+ treatment of large B-cell lymphoma...
Category: Clinical Trials, Pharmaceutical
Posted: May 14, 2024
Generis Welcomes Max Kelleher as New Chief Executive Officer
14 May 2024 -- London, UK -- Generis, creator of the cloud data, content and business process management platform CARA, today announced that Max Kelleher will be stepping into the...
Category: Biotechnology, Other
Posted: May 14, 2024
ERS Genomics appoints John E Milad as Chief Executive Officer
13 May 2024 -- Dublin, Ireland -- ERS Genomics, the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25...
Category: Drug Delivery, Drug Discovery
Posted: May 13, 2024
Verisense Health Elects Josh Tolkoff to its Board of Directors
Josh brings extensive medical device, investment and growth management experience to his new role 9 May 2024 -- Massachusetts, US -- Verisense Health, a digital health technology and data company,...
Category: Biotechnology, Other
Posted: May 9, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Gilead Sciences Appoints Peter Wickersham to Vice-President and General Manager in the UK and Ireland
7 May 2024 -- London, UK -- Gilead Sciences announced today the appointment of Peter Wickersham as vice-president and general manager for the UK and Ireland. In his new role,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
Barinthus Bio Names Experienced Physician, Leon Hooftman MD, as Chief Medical Officer
Dr Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, haematology, oncology and infectious diseases 1 May 2024 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical...
Category: BioManufacturing, Drug Discovery
Posted: May 1, 2024
ProBioGen Announces Change in Management
30 April 2024 -- Berlin, Germany -- ProBioGen AG, a premier contract development and manufacturing organisation (CDMO) and technology provider with extensive expertise in cell line engineering, process development and GMP...
Category: BioManufacturing, Other
Posted: April 30, 2024
Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer
Dale Levitzke joins as Dr Frank F Craig, current CEO and co-founder, announces his retirement after leading the company for 14 years 30 April 2024 -- Cambridge, UK -- Sphere...
Category: Biotechnology, Other
Posted: April 30, 2024
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programmes 23 April 2024 -- Oslo, Norway -- Calluna Pharma, a clinical stage company pioneering a...
Category: Other, Pharmaceutical
Posted: April 23, 2024
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children
Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...
Category: Pharmaceutical
Posted: April 9, 2024
G.ST Antivirals reports start of Phase 2 trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer
Phase 2 clinical trial started, first subject in on 2 April 2024 New CMO Ronald Bruce Turner MD, distinguished expert in the clinical research of rhinoviruses, to oversee trial and...
Category: Biotechnology, Clinical Trials
Posted: April 9, 2024
Gilead extends partnership with NHS England to eliminate hepatitis C by 2025
Since the commencement of the Strategic Procurement agreement in 2019, Gilead has worked in partnership with NHS England, non-profit organisations, and industry to help treat and cure over 84,000 people...
Category: Other, Pharmaceutical
Posted: April 8, 2024
Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services
18 March 2024 -- Minnesota, US, and Missouri, US -- Kindeva Drug Delivery, a global leader in drug-device combination products, today welcomes Jennifer Riter as vice president of Analytical Services to...
Category: Drug Delivery
Posted: March 18, 2024
